A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Tuesday, 7 July 2015

SPCs on the agenda, and a chance to save some money

If you are attending this year's C5 Life Sciences IP Summit (programme here) in Berlin on 22 to 23 October 2015, it has a session on SPCs that looks like this:
4:15 to 5:30 A Case-Law Review of the Jurisprudence on Supplementary Protection Certificates in Europe
  • Matthew Royle
    Taylor Wessing (United Kingdom)
  • Lessons learnt from C-493/12 (Lilly-HGS), C-631/13 (Forsgren), E-16/14 (Pharmaq-Intervet)
  • An overview of the pending referrals concerning SPCs before the CJEU
  • Understanding under which circumstances you can obtain an SPC in the context of antibody claims
  • Obtaining an SPC on combinations of active ingredients for new uses
  • Neurim’s, Medeva’s, Georgetown’s, AstraZeneca’s, Merck’s aftermath: an overview of the CJEU’s interpretation on development of a new indication from an old substance
IPKat blog readers can get a 15% reduction on the registration fee: details can be found here.